BioSpace News Archive

LimFlow SA today announced it has closed a $40 million (€36 million) oversubscribed Series D financing round.

Ingersoll Rand Inc. will issue its first-quarter earnings release after the market closes on May 4, 2022.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2022 after the close of trading on Tuesday, May 3.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, announced updated financial guidance for the full year 2022 to include the expected impact of the BioDelivery Sciences International Inc. acquisition.

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, announced that its management team will participate in the following virtual conferences in April.

Affini-T Therapeutics, Inc, a biotechnology company unlocking the power of T cells against oncogenic driver mutations, announced the appointments of Michael Varney, Ph.D., and Daniel Faga to its board of directors.

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, announced management will participate in the following upcoming virtual investor conferences in April 2022.

MiMedx Group, Inc., a transformational placental biologics company, announced it will sponsor a lunch symposium at the Symposium on Advanced Wound Care Spring on April 6-10 in Phoenix, Arizona.

Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY recently published a study in Nature Communications using network modeling to identify novel targets for treating patients with early-stage invasive lung adenocarcinoma.

Respira Therapeutics, Inc. announced today that the first patient in the United States has been dosed in the multicenter trial of its lead product candidate, RT234-PAH (vardenafil administered as a dry powder inhaled treatment).